{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:38:14Z","timestamp":1787870294289,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P51 OD010425"],"award-info":[{"award-number":["P51 OD010425"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI120176"],"award-info":[{"award-number":["UM1 AI120176"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI1480555"],"award-info":[{"award-number":["U01 AI1480555"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61 AI49965"],"award-info":[{"award-number":["R61 AI49965"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.xphs.2020.01.016","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T02:27:51Z","timestamp":1580264871000},"page":"1789-1801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101"],"prefix":"10.1016","volume":"109","author":[{"given":"Simone","family":"Perazzolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Shireman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"McConnachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Koehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Kinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonsok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny D.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7588","key":"10.1016\/j.xphs.2020.01.016_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1 replication maintains the tissue reservoir during therapy","volume":"530","author":"Lorenzo-Redondo","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.xphs.2020.01.016_bib2","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.4411","article-title":"Defining total-body AIDS-virus burden with implications for curative strategies","volume":"23","author":"Estes","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.xphs.2020.01.016_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tim.2019.02.009","article-title":"The promise of long-acting antiretroviral therapies: from need to manufacture","volume":"27","author":"Gendelman","year":"2019","journal-title":"Trends Microbiol"},{"issue":"1","key":"10.1016\/j.xphs.2020.01.016_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jps.23773","article-title":"Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems","volume":"103","author":"Kraft","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"issue":"10101","key":"10.1016\/j.xphs.2020.01.016_bib5","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.xphs.2020.01.016_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5588\/ijtld.17.0486","article-title":"Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges","volume":"22","author":"Swindells","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.xphs.2020.01.016_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"10.1016\/j.xphs.2020.01.016_bib8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/QAD.0000000000001405","article-title":"Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma","volume":"31","author":"Kraft","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.xphs.2020.01.016_bib9","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.xphs.2018.07.032","article-title":"Three HIV drugs, atazanavir, ritonavir and tenofovir co-formulated in drug-combination nanoparticles exhibit long-acting and lymphocyte targeting properties in non-human primates","volume":"107","author":"Perazzolo","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.01.016_bib10","first-page":"1","article-title":"Long-acting profile of 4 drugs in 1 anti-HIV nanosuspension in nonhuman primates for 5 weeks after a single subcutaneous injection","volume":"30","author":"McConnachie","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"issue":"25","key":"10.1016\/j.xphs.2020.01.016_bib11","doi-asserted-by":"crossref","first-page":"E2512","DOI":"10.1073\/pnas.1406554111","article-title":"Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence","volume":"111","author":"Freeling","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2020.01.016_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jconrel.2018.02.003","article-title":"Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation","volume":"275","author":"Kraft","year":"2018","journal-title":"J\u00a0Control Release"},{"issue":"5-6","key":"10.1016\/j.xphs.2020.01.016_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/1061186X.2018.1433681","article-title":"Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed\u00a0mapping of lymph vessels, nodes and abnormalities","volume":"26","author":"Kraft","year":"2018","journal-title":"J\u00a0Drug Target"},{"issue":"9","key":"10.1016\/j.xphs.2020.01.016_bib14","doi-asserted-by":"crossref","first-page":"e13082","DOI":"10.1371\/journal.pone.0013082","article-title":"Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging","volume":"5","author":"Bui","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.xphs.2020.01.016_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1166\/jbn.2012.1422","article-title":"Cell tolerability and biodistribution in mice of indocyanine green-loaded lipid nanoparticles","volume":"8","author":"Navarro","year":"2012","journal-title":"J\u00a0Biomed Nanotechnol"},{"issue":"4","key":"10.1016\/j.xphs.2020.01.016_bib16","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.nano.2013.10.004","article-title":"Secretion of intestinal goblet cells: a novel\u00a0excretion pathway of nanoparticles","volume":"10","author":"Zhao","year":"2014","journal-title":"Nanomedicine"},{"issue":"11","key":"10.1016\/j.xphs.2020.01.016_bib17","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1128\/AAC.00869-15","article-title":"A\u00a0simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry","volume":"59","author":"Koehn","year":"2015","journal-title":"Antimicrobial Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2020.01.016_bib18","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1038\/s41467-018-06730-z","article-title":"Establishing the effects of mesoporous silica nanoparticle properties on in\u00a0vivo disposition using imaging-based pharmacokinetics","volume":"9","author":"Dogra","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.xphs.2020.01.016_bib19","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.1021\/acsnano.5b03184","article-title":"Physical principles of nanoparticle cellular endocytosis","volume":"9","author":"Zhang","year":"2015","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.xphs.2020.01.016_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"In\u00a0vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J\u00a0Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2020.01.016_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.nantod.2014.04.011","article-title":"Intracellular delivery of nanomaterials: how to catch endosomal escape in the act","volume":"9","author":"Martens","year":"2014","journal-title":"Nano Today"},{"issue":"5","key":"10.1016\/j.xphs.2020.01.016_bib22","doi-asserted-by":"crossref","first-page":"e1003586","DOI":"10.1371\/journal.pcbi.1003586","article-title":"Mathematical modeling reveals kinetics of l ymphocyte recirculation in the whole organism","volume":"10","author":"Ganusov","year":"2014","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.xphs.2020.01.016_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fimmu.2019.00194","article-title":"Fate of a naive T cell: a stochastic journey","volume":"10","author":"de la Higuera","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.xphs.2020.01.016_bib24","first-page":"315","article-title":"Lopinavir\/ritonavir (ABT-378\/r)","volume":"3","author":"Qazi","year":"2002","journal-title":"Expert Opin Drug Deliv"},{"issue":"7","key":"10.1016\/j.xphs.2020.01.016_bib25","doi-asserted-by":"crossref","first-page":"e40382","DOI":"10.1371\/journal.pone.0040382","article-title":"Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection","volume":"7","author":"Duwal","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.xphs.2020.01.016_bib26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), bis (isopropyloxymethylcarbonyl) PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrobial Agents Chemother"},{"issue":"5-6","key":"10.1016\/j.xphs.2020.01.016_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/1061186X.2017.1419363","article-title":"Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook","volume":"26","author":"Mu","year":"2018","journal-title":"J\u00a0Drug Target"},{"key":"10.1016\/j.xphs.2020.01.016_bib28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front Pharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920300228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920300228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:29:18Z","timestamp":1758360558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920300228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0022354920300228"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.01.016","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}